Perspective Therapeutics is a biotech company with promising oncology applications in radiopharmaceuticals. Find out why I ...

Perspective's promising PRRT trial results and solid financial position make CATX stock an attractive long-term investment ...

Perspective (NYSE:CATX) increased its cash and short-term investments to $267.8 million as of September 30, 2024, compared to $9.2 million at the end of 2023. This funding is projected to support ...

Perspective Therapeutics, Inc. (NYSE:CATX) is a promising small-cap company ... unresectable or metastatic somatostatin ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Shares of CATX opened at $3.47 on Friday. Perspective Therapeutics has a 52 week low of $2.28 and a ...

Perspective Therapeutics Inc (CATX) stock saw a decline, ending the day at $3.71 which represents a decrease of $-0.29 or -7.25% from the prior close of $4. The stock opened at $4.01 and touched a low ...

State Street Corp grew its position in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 119.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 2,190,239 ...

在一个波动剧烈的交易日中，CATX股票暴跌至52周低点，达到2.92美元的价格水平。根据 InvestingPro 的数据，该股票的RSI指标显示处于超卖区域，而分析师的目标价范围从6美元到21美元不等，暗示从当前水平可能存在上涨空间。这一显著下跌反映了该公司正经历一个充满挑战的时期，其股价在过去一年里一直难以获得动力。CATX市值约为2.01亿美元，InvestingPro给出的整体财务健康评分 ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report). The company’s shares closed yesterday at $6.96.

JonesResearch analyst Justin Walsh views the selloff in shares Perspective Therapeutics (CATX) yesterday after the ... somatostatin receptor type 2 neuroendocrine tumors who have not received ...

Truist Financial analyst Nicole Germino assigned a Buy rating to Perspective Therapeutics (CATX – Research Report) today and set a price target of $21.00. The company’s shares closed yesterday ...